Nisin and its application in oral diseases

Chan, Ka Teng; Song, Xin; Shen, Leyao; Liu, Nian; Zhou, Xuedong; Cheng, Lei; Chen, Jing

doi:10.1016/j.jff.2023.105559

Cited by 12 publications

(4 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, nisin-loaded PCL nanoparticles have been suggested as a potential strategy for preventing vaginal candidiasis by inhibiting C. albicans growth ( de Abreu et al, 2016 ). Further, the use of nisin as an additive may help reduce the use of antibiotics, minimize side effects, and prevent resistance in clinical scenarios ( Chan et al, 2023 ). Therefore, nanoformulations or combination treatment therapies that include nisin may hold promise for combating fungal infections and entail exciting prospects for future applications.…”

Section: Discussionmentioning

confidence: 99%

“…lactis and was approved by the US Food and Drug Agency in 1988, and it generally recognized as safe ( de Arauz et al, 2009 ). Twelve natural variants of nisin have been reported so far, and several bioengineered variants have been developed for various biological applications ( Chan et al, 2023 ). Currently, the focus of research on nisin is shifting from food preservation to its therapeutic use for the treatment of bacterial infections.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antifungal activity of nisin against clinical isolates of azole-resistant Candida tropicalis

Gao,

Ji,

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

The rapid emergence of invasive infections caused by azole-resistant Candida tropicalis has become a public health concern, and there is an urgent need for alternative treatment strategies. Studies have demonstrated the antibacterial effects of nisin, a well-known peptide naturally produced by Lactococcus lactis subsp. lactis. However, there is scant information about the antifungal effect of nisin against C. tropicalis. The present study aims to investigate the in vitro antifungal activity of nisin against clinical isolates of azole-resistant C. tropicalis strains, as well as its inhibitory effect on biofilm formation. A total of 35 C. tropicalis strains isolated from patients with invasive fungal infections were divided into the azole-resistant group and the azole-sensitive group, containing 21 and 14 strains, respectively. The relative expression levels of the ERG11 and UPC2 genes in the azole-resistant group were higher than those in the azole-sensitive group (p < 0.0001), while no significant differences were observed in the expression levels of the MDR1 and CDR1 genes. The minimum inhibitory concentration of nisin against C. tropicalis ranged from 2 to 8 μg/mL. Nisin treatment inhibited the growth of azole-resistant C. tropicalis, with over a four-fold reduction in OD600 nm values observed at the 8-h time point, while it promoted the transition of C. tropicalis from the spore phase to the hyphal phase, as observed on cryo-scanning electron microscopy. The results of biofilm quantification using crystal violet staining indicated a significant decrease in OD570 nm values in the nisin-treated group compared to the controls (p < 0.0001). Among the 21 azole-resistant C. tropicalis strains, the biofilm formation was inhibited in 17 strains (17/21, 81%), and more than 85% inhibition of biofilm formation was observed in the representative strains. With regard to the molecular mechanisms, the expression of the BCR1 and UPC2 genes in the azole-resistant strains was down-regulated on nisin treatment (p < 0.05). In conclusion, we demonstrated, for the first time, that nisin has antifungal activity and significant anti-biofilm activity against clinical isolates of azole-resistant C. tropicalis strains. Based on the findings, nisin could be a promising alternative antifungal agent for combating azole-resistant C. tropicalis infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antifungal activity of nisin against clinical isolates of azole-resistant Candida tropicalis

Gao,

Ji,

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…An approach using whole-cell Listeria biosensor strains has already shown great potential for testing novel compounds ( Desiderato et al, 2021 ; Reich et al, 2022 ). The pore-forming and lipid II-aggregating lantibiotic nisin ( Brötz et al, 1998 ; Scherer et al, 2015 ), which has shown potential as a food and feed additive ( Younes et al, 2017 ; Ibarra-Sánchez et al, 2020 ; Kierończyk et al, 2020 ) as well as in medical applications ( Shin et al, 2016 ; O'Reilly et al, 2023 ; Chan et al, 2023 ), is the only bacteriocin that is approved by the FDA and EFSA as a biopreservative and food additive ( Younes et al, 2017 ; Chan et al, 2023 ). Thus, nisin is an ideal standard bacteriocin for the evaluation of whole-cell biosensors and for comparison with other methods and sample types, e.g., culture supernatants of natural producers.…”

Section: Introductionmentioning

confidence: 99%

Time-resolved cell-to-cell heterogeneity of Listeria innocua after nisin exposure

Fante,

Desiderato,

Riedel

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The use of bacteriocins is a promising approach for addressing the immense threat of food-borne and drug-resistant pathogens. In recent years screening platforms for novel bacteriocins using whole-cell biosensors have been established. During screening cell-to-cell heterogeneity is currently neglected but might play a crucial role in signal development of the whole-cell biosensor after bacteriocin exposure. In this study, we explored the temporal dynamics of the signal heterogeneity of the biosensor Listeria innocua LMG2785/pNZpHin2Lm after nisin exposure using microfluidic single-cell analysis. The results provided novel and detailed insights into the dynamics of cell-to-cell heterogeneity in L. innocua LMG2785/pNZpHin2Lm at different nisin concentrations with a high spatio-temporal resolution. Furthermore, the formation of subpopulations during bacteriocin exposure was observed. In-depth single-cell tracking even revealed the regeneration of disrupted cells and recovery of pH homeostasis in rare instances. These findings are highly important for the future design and execution of bacteriocin assays and for the interpretation of fluorescence signal development at the population level after exposure to different concentrations of bacteriocins (here, nisin), as well as for obtaining deeper insights into single-cell persistence strategies to quantify the efficacy and efficiency of novel bacteriocins.

show abstract

“…An approach using whole-cell Listeria biosensor strains has already shown great potential for testing novel compounds (Desiderato et al, 2021;Reich et al, 2022). The pore-forming and lipid II-aggregating lantibiotic nisin (Brötz et al, 1998;Scherer et al, 2015), which has shown potential as a food and feed additive (Younes et al, 2017;Ibarra-Sánchez et al, 2020;Kierończyk et al, 2020) as well as in medical applications (Shin et al, 2016;O'Reilly et al, 2023;Chan et al, 2023), is the only bacteriocin that is approved by the FDA and EFSA as a biopreservative and food additive (Younes et al, 2017;Chan et al, 2023). Thus, nisin is an ideal standard bacteriocin for the evaluation of whole-cell biosensors and for comparison with other methods and sample types, e.g., culture supernatants of natural producers.…”

Section: Introductionmentioning

confidence: 99%

DataSheet1.pdf

View full text Add to dashboard Cite

Nisin and its application in oral diseases

Cited by 12 publications

References 114 publications

Antifungal activity of nisin against clinical isolates of azole-resistant Candida tropicalis

Antifungal activity of nisin against clinical isolates of azole-resistant Candida tropicalis

Time-resolved cell-to-cell heterogeneity of Listeria innocua after nisin exposure

DataSheet1.pdf

Contact Info

Product

Resources

About